Screener
Alumis Inc. ALMS Q3 2026 earnings
Reported November 12, 2026 · After market close
Revenue$1.9MBeat by $7.0K
EPS-$0.73Beat by $0.03
Revenue estimate$1.9M
EPS estimate-$0.76
“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib's highly competitive profile in moderate-to-severe plaque psoriasis. The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”
Next report
Date not yet announcedValuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Alumis Inc. report Q3 2026 earnings?
- Alumis Inc. (ALMS) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Alumis Inc.'s Q3 2026 revenue and EPS?
- Alumis Inc. reported revenue of $1.9M and eps of $-0.73 for Q3 2026.
- Did Alumis Inc. beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $1.9M by $7.0K. EPS beat the consensus estimate of $-0.76 by $0.03.
- How did Alumis Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 7.7% from $2.1M a year earlier and eps grew 31.1% from $-1.06.
- Where can I find Alumis Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001847367-26-000022) and the 10-Q periodic report (0001847367-26-000024) directly on SEC EDGAR. The filing index links above go to sec.gov.
